<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00966225</url>
  </required_header>
  <id_info>
    <org_study_id>LIP-01-2009-1</org_study_id>
    <nct_id>NCT00966225</nct_id>
  </id_info>
  <brief_title>LIP-01 in Hypercholesterolemia</brief_title>
  <official_title>An Open-label Dose-finding Study of LIP-01 in Otherwise Healthy Individuals With Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Afexa Life Sciences Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Afexa Life Sciences Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine a safe and tolerable dose of LIP-01
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine a safe and tolerable dose of LIP-01</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>One gram LIP-01 per day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One gram LIP-01 per day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Two grams LIP-01 per day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two grams LIP-01 per day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.333 grams LIP-01 per day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.333 grams LIP-01 per day for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>LIP-01</intervention_name>
    <description>comparison of different dosages of natural health product</description>
    <arm_group_label>One gram LIP-01 per day</arm_group_label>
    <arm_group_label>Two grams LIP-01 per day</arm_group_label>
    <arm_group_label>0.333 grams LIP-01 per day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18-75 years

          -  Plasma total-cholesterol &gt;5.2 mmol/L (&gt; 200 mg/dL)

          -  Willingness to adhere to the requirements of the protocol, including availability for
             follow-up visits and donation of blood samples

          -  Willingness and ability to sign written informed consent

          -  Women of child bearing capacity who agree to use an acceptable form of birth control
             during the trial [i.e., oral contraception, reliable use of a double-barrier method
             (e.g., condom and diaphragm, condom and foam, condom and sponge), IUD or tubal
             ligation]

        Exclusion Criteria:

          -  Plasma triglycerides &gt; 4.0 mmol/L (&gt; 354 mg/dL)

          -  Plasma LDL ≥ 5.0 mmol/L (≥ 195 mg/dL)

          -  Current coronary artery/ cardiovascular disease or history of a cardiovascular event
             (stroke, transient ischemic attack, myocardial infarction, angioplasty or coronary
             artery bypass grafting, angina pectoris)

          -  Moderate/high risk of coronary artery/ cardiovascular disease

          -  Diabetes mellitus

          -  Uncorrected hypothyroidism

          -  Other significant metabolic endocrine disease

          -  Uncontrolled hypertension (&gt;160 systolic or &gt;100 diastolic)

          -  Active liver disease (ALT &gt;2x normal)

          -  Significant gastrointestinal disease

          -  Acute inflammatory disease

          -  Significant kidney disease (calculated by eGFR &lt;60 mL/min)

          -  Any other significant medical condition which, in the opinion of the investigator,
             could compromise patient safety or confound trial results

          -  Any significant/relevant surgery within the last year

          -  Use of lipid-lowering drugs

          -  Treatment within the previous 6 months with any medication that is known to affect
             lipid or lipoprotein levels (such as statins, fibric acid derivatives, bile acid
             sequestrants, ezetimibe, nicotinic acid)

          -  Regular use of natural health products or dietary supplements known to affect lipid or
             lipoprotein levels (omega-3 fatty acids, green tea extracts, guggulipid, psyllium,
             plant sterols, policosanols). If the participants agree to stop taking these products
             prior to study entry and for the duration of the study, they can participate in the
             study.

          -  Pregnant or lactating women

          -  Known allergy to any ingredient in the study product, including: Coptis chinensis,
             Ilex kudingcha, microcrystalline cellulose and magnesium stearate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Lewanczuk, MD, PhD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medicus Research, LLC</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Northern Alberta Clinical Trials and Research Centre</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2009</study_first_submitted>
  <study_first_submitted_qc>August 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2009</study_first_posted>
  <last_update_submitted>January 26, 2012</last_update_submitted>
  <last_update_submitted_qc>January 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

